查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1504047

抗糖尿病市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、類型、給藥途徑、配銷通路、地區和競爭細分，2019-2029F

Antidiabetics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Type, By Route of Administration, By Distribution Channel,By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球抗糖尿病藥物市場價值為810.4 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為10.51%。的藥物，正在見證全球糖尿病患病率上升推動了大幅成長。由於人口老化、城市化、久坐的生活方式和肥胖率上升等因素，糖尿病患者數量不斷增加，推動了這一成長。抗糖尿病藥物分為胰島素治療和非胰島素治療。胰島素對於第 1 型糖尿病管理至關重要，並且擴大用於第 2 型糖尿病，繼續主導市場。先進胰島素製劑和輸送系統（包括長效胰島素類似物和胰島素幫浦）的開發提高了治療順從性和患者便利性。在非胰島素領域，市場正在隨著 GLP-1 受體激動劑、SGLT2 抑制劑和 DPP-4 抑制劑等創新藥物類別的擴展而不斷擴大，這些藥物可提供顯著的血糖控制和心血管益處。聯合療法的引入，整合了多種作用機制，透過改善治療結果和簡化患者的治療方案進一步提振了市場。

市場概況
預測期 2025-2029
2023 年市場規模 810.4億美元
2029 年市場規模 1,462.3億美元
2024-2029 年複合年成長率 10.51%
成長最快的細分市場 GLP-1受體激動劑
最大的市場 北美洲

血糖監測設備的技術進步也推動了市場的成長，包括連續血糖監測儀 (CGM) 和整合胰島素輸送系統，可提供即時資料和個人化治療調整。數位健康平台和遠距醫療正在成為糖尿病管理不可或缺的一部分，實現遠端監控和諮詢，這在 COVID-19 大流行之後尤其有價值。

主要市場促進因素

糖尿病盛行率增加

胰島素治療的進展

主要市場挑戰

治療費用高

獲得醫療保健的機會有限

主要市場趨勢

新型非胰島素療法的出現

聯合療法

細分市場洞察

藥品類別見解

類型洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（胰島素、GLP-1 受體激動劑、DPP-4 抑制劑、SGLT2 抑制劑等）
    • 按類型（類型 1、類型 2）
    • 依給藥途徑（口服、皮下、靜脈注射）
    • 依配銷通路（網路藥局、醫院藥局、零售藥局）
    • 按公司分類 (2023)
    • 按地區
  • 市場地圖

第 6 章：北美抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最近的發展

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • AstraZeneca Plc
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Pfizer, Inc.
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 24130

Global Antidiabetics Market was valued at USD 81.04 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 10.51% through 2029. The global antidiabetics market, encompassing a broad array of medications aimed at managing diabetes mellitus, is witnessing substantial growth driven by the rising prevalence of diabetes worldwide. This growth is propelled by an increasing number of diabetic patients due to factors such as aging populations, urbanization, sedentary lifestyles, and rising obesity rates. Antidiabetic drugs are categorized into insulin and non-insulin therapies. Insulin, essential for Type 1 diabetes management and increasingly used in Type 2 diabetes, continues to dominate the market. The development of advanced insulin formulations and delivery systems, including long-acting insulin analogs and insulin pumps, enhances treatment adherence and patient convenience. In the non-insulin segment, the market is expanding with innovative classes of drugs such as GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors, which offer significant glycemic control and cardiovascular benefits. The introduction of combination therapies, integrating multiple mechanisms of action, has further bolstered the market by improving therapeutic outcomes and simplifying regimens for patients.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 81.04 Billion
Market Size 2029USD 146.23 Billion
CAGR 2024-202910.51%
Fastest Growing SegmentGLP-1 receptor agonists
Largest MarketNorth America

The market's growth is also fueled by technological advancements in blood glucose monitoring devices, including continuous glucose monitors (CGMs) and integrated insulin delivery systems, which provide real-time data and personalized treatment adjustments. Digital health platforms and telemedicine are becoming integral to diabetes management, enabling remote monitoring and consultations, which are particularly valuable in the wake of the COVID-19 pandemic.

Key Market Drivers

Increasing Prevalence of Diabetes

The increasing prevalence of diabetes is a pivotal driver of the global antidiabetics market, significantly influencing its growth and expansion. Diabetes mellitus, a chronic condition marked by elevated blood glucose levels, is becoming more widespread due to several converging factors. One of the primary contributors is the aging global population. Urbanization is another critical factor. The shift from rural to urban living often leads to lifestyle changes that contribute to the development of diabetes. Urban environments typically promote sedentary behaviors, with less physical activity and greater access to high-calorie, processed foods, increasing the risk of obesity-a major risk factor for diabetes. The fast-paced urban lifestyle can lead to stress and poor dietary habits, both of which are associated with the onset of diabetes.

Sedentary lifestyles, which are prevalent in both urban and rural settings, also play a significant role. The rise of technology and digital entertainment means that more people, including children and adolescents, spend extended periods inactive, contributing to obesity and insulin resistance. According to the IDF Diabetes Atlas highlighting current statistics, data, and forecasts regarding the worldwide ramifications of diabetes- As of 2021, there were 537 million adults, equating to 1 in 10 individuals, living with diabetes. Projections indicate this figure is poised to escalate to 643 million by 2030 and further to 783 million by 2045. The predominant majority of these cases are attributed to type 2 diabetes. This dramatic increase underscores the urgent need for effective diabetes management solutions.

This growing patient population drives the demand for antidiabetic medications and devices. Patients require a variety of treatments, from oral medications and insulin to advanced glucose monitoring devices. As diabetes becomes more common, healthcare systems worldwide are increasingly prioritizing diabetes management, leading to a proportional rise in the antidiabetics market. The pharmaceutical and medical device industries are responding with innovations and enhanced products designed to improve glycemic control, patient adherence, and overall quality of life for those living with diabetes. Thus, the rising prevalence of diabetes directly fuels the expansion of the global antidiabetics market, making it a crucial area of focus for healthcare providers and manufacturers alike.

Advancements in Insulin Therapy

Advancements in insulin therapy have been transformative for diabetes management, particularly for individuals with Type 1 diabetes and those with advanced Type 2 diabetes. Insulin therapy remains a critical component of treatment, providing essential regulation of blood glucose levels. Recent innovations in insulin formulations and delivery systems have significantly enhanced the efficacy and convenience of insulin therapy, driving substantial growth in the global antidiabetics market.

One of the most notable advancements is the development of long-acting insulin analogs. These formulations, such as insulin glargine and insulin degludec, offer a more stable and prolonged glucose control, reducing the frequency of injections required and providing a more consistent therapeutic effect. This stability not only improves glycemic control but also reduces the risk of hypoglycemia, a common concern with older insulin types. Patients benefit from fewer fluctuations in blood glucose levels, leading to better overall health outcomes and increased adherence to prescribed regimens.

The advent of smart insulin delivery systems has revolutionized diabetes care. Insulin pumps, which deliver continuous subcutaneous insulin infusion, have become increasingly sophisticated. These devices now often incorporate continuous glucose monitoring (CGM) systems, providing real-time data that allows for precise insulin dosing adjustments. The integration of CGMs with insulin pumps has enabled the development of closed-loop systems, or "artificial pancreas" technologies, which automatically adjust insulin delivery based on glucose readings. This automation mimics the natural function of the pancreas more closely, significantly improving glycemic control and reducing the burden of diabetes management on patients.

Insulin pens have also seen significant advancements. Modern insulin pens are equipped with features like dose memory, dose adjustment buttons, and compatibility with smart devices that track injection data. These enhancements make insulin administration easier and more accurate, fostering better adherence to treatment plans.

Key Market Challenges

High Cost of Treatment

One of the primary challenges hindering the global antidiabetics market is the high cost of treatment. The expenses associated with diabetes management are significant, encompassing not only medication costs but also the expenses for continuous glucose monitors (CGMs), insulin pumps, and other related medical supplies. Advanced insulin formulations and newer drug classes, such as GLP-1 receptor agonists and SGLT2 inhibitors, often come with a high price tag, making them less accessible to a large portion of the population, particularly in low- and middle-income countries. Even in high-income nations, the cost burden can be substantial for uninsured or underinsured patients. This financial strain can lead to inadequate treatment adherence and suboptimal disease management, increasing the risk of complications and overall healthcare costs.The high cost of antidiabetic treatments also puts pressure on healthcare systems and insurance providers, potentially leading to restrictive formularies and limited access to the most effective therapies. Patients may find themselves limited to older, less effective treatments, which can compromise their health outcomes. The cost of advanced technologies like CGMs and insulin pumps, while beneficial, adds to the overall economic burden, making comprehensive diabetes care financially unattainable for many.

Limited Access to Healthcare

Limited access to healthcare is another significant barrier affecting the global antidiabetics market. In many regions, particularly in rural and underserved areas, there is a profound lack of healthcare infrastructure and professionals trained in diabetes management. This deficiency in resources hampers early diagnosis and timely treatment, leading to higher rates of complications and mortality associated with diabetes. the availability of essential diabetes medications and advanced treatment options, such as continuous glucose monitors (CGMs) and insulin pumps, is often severely restricted in these areas. Patients in low-resource settings frequently face the challenge of traveling long distances to reach healthcare facilities, which can be both time-consuming and costly. This travel burden, coupled with the scarcity of healthcare providers, often results in delayed or inadequate care.

Socioeconomic factors further exacerbate these access issues. Low income, lack of health insurance, and limited health literacy make it difficult for patients to receive continuous and comprehensive care. Many individuals cannot afford regular medical check-ups or the necessary medications and technologies to manage their diabetes effectively. The lack of health literacy also means that patients may not fully understand their condition or the importance of adhering to treatment plans. Efforts to improve healthcare access must focus on expanding healthcare infrastructure, increasing the availability of trained healthcare professionals, and implementing community-based programs to educate and support patients in managing their condition effectively.

Key Market Trends

Emergence of Novel Non-Insulin Therapies

The emergence of novel non-insulin therapies has significantly transformed the landscape of diabetes management, particularly for Type 2 diabetes. The rapid expansion of the non-insulin segment of the antidiabetics market is driven by the introduction of innovative drug classes such as glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. These therapies offer distinct mechanisms of action that improve glycemic control and provide additional health benefits, making them highly effective and appealing options for both patients and healthcare providers.

GLP-1 receptor agonists, such as exenatide and liraglutide, mimic the incretin hormone GLP-1, enhancing insulin secretion in response to meals and inhibiting glucagon release. They also slow gastric emptying, which promotes satiety and weight loss, addressing a common issue in Type 2 diabetes management. Some GLP-1 receptor agonists have demonstrated cardiovascular benefits, reducing the risk of major adverse cardiovascular events in high-risk patients. SGLT2 inhibitors, including canagliflozin and empagliflozin, function by preventing the reabsorption of glucose in the kidneys, leading to increased glucose excretion in urine. This mechanism not only lowers blood glucose levels but also contributes to weight loss and a reduction in blood pressure. SGLT2 inhibitors have also been shown to provide renal protection and cardiovascular benefits, making them a valuable addition to diabetes treatment regimens.

DPP-4 inhibitors, such as sitagliptin and saxagliptin, work by blocking the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones. This inhibition prolongs the action of incretins, enhancing insulin secretion and suppressing glucagon production, thereby improving blood glucose control. DPP-4 inhibitors are generally well-tolerated and have a low risk of hypoglycemia, making them suitable for a broad range of patients.

The effectiveness and favorable safety profiles of these novel non-insulin therapies have made them popular choices in diabetes management. They offer personalized treatment options that can be tailored to the specific needs and conditions of individual patients. As these therapies continue to gain acceptance and demonstrate their benefits, the non-insulin segment of the antidiabetics market is expected to see sustained growth.

Combination Therapies

Combination therapies in diabetes management are increasingly recognized for their ability to provide comprehensive treatment by integrating multiple mechanisms of action. This approach combines different classes of antidiabetic drugs into a single regimen, addressing various aspects of diabetes pathophysiology and offering numerous benefits that enhance treatment efficacy and patient adherence. Metformin, a first-line therapy, primarily works by reducing hepatic glucose production and improving insulin sensitivity. When combined with SGLT2 inhibitors, which promote glucose excretion via the kidneys, or GLP-1 receptor agonists, which enhance insulin secretion and promote satiety, the therapeutic outcomes are significantly enhanced. This multifaceted approach results in better glycemic control, weight loss, and improved cardiovascular health compared to monotherapy.

The ability to address multiple disease mechanisms with a single therapy regimen simplifies medication schedules, which is crucial for improving patient compliance. Diabetes patients often face complex treatment plans involving multiple medications with different dosing schedules. Combination therapies reduce this complexity by decreasing the number of pills a patient needs to take, making it easier to adhere to the treatment regimen. This simplification not only improves patient adherence but also enhances overall treatment satisfaction and outcomes.

Combination therapies offer the advantage of targeting both fasting and postprandial blood glucose levels, providing a more comprehensive glycemic control. This dual action is particularly beneficial in managing Type 2 diabetes, which is characterized by multiple underlying pathophysiological defects.

The growing popularity of combination therapies is also driven by their proven safety and efficacy profiles. Clinical trials and real-world studies have demonstrated that these therapies can achieve superior glycemic control with a lower risk of side effects compared to higher doses of monotherapy. This balance of efficacy and safety makes combination therapies an attractive option for both patients and healthcare providers.

Segmental Insights

Drug Class Insights

Based on the Drug Class, GLP-1 receptor agonists emerged as the dominant segment in the Global Antidiabetics Market in 2023. One key factor driving the dominance of GLP-1 receptor agonists is their multifaceted mechanism of action, which addresses several aspects of diabetes pathophysiology. GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner, suppress glucagon secretion, slow gastric emptying, and promote satiety, resulting in improved glycemic control, weight loss, and cardiovascular benefits. This comprehensive approach to diabetes management has made GLP-1 receptor agonists highly attractive to both patients and healthcare providers.

Clinical trials and real-world evidence have consistently demonstrated the efficacy and safety of GLP-1 receptor agonists in managing Type 2 diabetes. These drugs have shown significant reductions in HbA1c levels, body weight, and cardiovascular events, making them a preferred choice for patients with diabetes and comorbidities. The introduction of newer and more convenient formulations of GLP-1 receptor agonists, such as once-weekly injectables and oral tablets, has further boosted their market dominance. These formulations offer improved patient convenience and adherence compared to daily injections, expanding the reach of GLP-1 receptor agonists to a broader patient population.

Type Insights

Based on the Type, In 2023, Type 2 diabetes emerged as the dominant segment in the global antidiabetics market. One significant factor driving the dominance of Type 2 diabetes in the antidiabetics market is its considerably higher prevalence worldwide compared to Type 1 diabetes. Type 2 diabetes accounts for the vast majority of diabetes cases globally, with an increasing prevalence driven by factors such as aging populations, sedentary lifestyles, unhealthy diets, and rising obesity rates. The sheer number of individuals affected by Type 2 diabetes translates to a larger patient population requiring ongoing management and treatment, driving demand for antidiabetic medications and therapies.

The complex nature of Type 2 diabetes, which often involves multiple underlying metabolic abnormalities and comorbidities, necessitates a multifaceted approach to treatment. This includes lifestyle modifications, oral antidiabetic medications, injectable therapies such as insulin and GLP-1 receptor agonists, and adjunctive treatments to manage associated conditions like hypertension and dyslipidemia. The diverse range of treatment options available for Type 2 diabetes reflects the complexity of the disease and the need for personalized treatment approaches tailored to individual patient needs.

Regional Insights

In 2023, North America emerged as the dominant region in the global antidiabetics market, holding the largest market share. This dominance can be attributed to several key factors that have contributed to the robust growth and prominence of the antidiabetics market in the region. One of the primary drivers of North America's dominance in the global antidiabetics market is the high prevalence of diabetes within the region. North America has one of the highest diabetes prevalence rates globally, with millions of individuals affected by the condition. The significant burden of diabetes has led to a correspondingly high demand for antidiabetic medications and therapies, driving market growth.

North America boasts advanced healthcare infrastructure and a well-established pharmaceutical industry, facilitating the development, manufacturing, and distribution of antidiabetic drugs and devices. The region is home to numerous pharmaceutical companies and research institutions dedicated to diabetes research and innovation, leading to the introduction of novel therapies and treatment modalities. robust public health initiatives and awareness campaigns aimed at diabetes prevention, early detection, and management have further underscored the importance of diabetes care in North America. These efforts have contributed to increased screening, diagnosis, and treatment rates, driving market growth within the region.

Key Market Players

AstraZeneca Plc

Bayer AG

Takeda Pharmaceutical Company Limited

Eli Lilly and Company

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

Pfizer, Inc.

Johnson & Johnson

Merck KGaA

Novartis AG

Report Scope:

In this report, the Global Antidiabetics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antidiabetics Market, By Drug Class:

    Insulin GLP-1 Receptor Agonists DPP- 4 Inhibitors SGLT2 Inhibitors Others

Antidiabetics Market, By Type:

    Type 1 Type 2

Antidiabetics Market, By Route of Administration:

    Oral Subcutaneous Intravenous

Antidiabetics Market, By Distribution Channel:

    Online pharmacies Hospital Pharmacies Retail pharmacies

Antidiabetics Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antidiabetics Market.

Available Customizations:

Global Antidiabetics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Antidiabetics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Others)
    • 5.2.2. By Type (Type 1, Type 2)
    • 5.2.3. By Route of Administration (Oral, Subcutaneous, Intravenous)
    • 5.2.4. By Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail pharmacies)
    • 5.2.5. By Company (2023)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Antidiabetics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antidiabetics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Mexico Antidiabetics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Canada Antidiabetics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Distribution Channel

7. Europe Antidiabetics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Antidiabetics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Germany Antidiabetics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Antidiabetics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Antidiabetics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Antidiabetics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Antidiabetics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Antidiabetics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Antidiabetics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. South Korea Antidiabetics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. Japan Antidiabetics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Antidiabetics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. South America Antidiabetics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Antidiabetics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. Argentina Antidiabetics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Colombia Antidiabetics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Antidiabetics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Antidiabetics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Saudi Arabia Antidiabetics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. UAE Antidiabetics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. AstraZeneca Plc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Bayer AG
  • 14.3. Takeda Pharmaceutical Company Limited
  • 14.4. Eli Lilly and Company
  • 14.5. Boehringer Ingelheim International GmbH
  • 14.6. Bristol-Myers Squibb Company
  • 14.7. Pfizer, Inc.
  • 14.8. Johnson & Johnson
  • 14.9. Merck KGaA
  • 14.10. Novartis AG

15. Strategic Recommendations

16. About Us & Disclaimer